Agios Pharmaceuticals, Inc. (AGIO)
After hours:
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 383
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Brian M. Goff M.B.A. | CEO & Director | 1.23M | N/A | 1969 |
| Ms. Cecilia Jones | Chief Financial Officer | 403.36k | N/A | 1975 |
| Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 660.33k | N/A | 1978 |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 769.2k | N/A | 1980 |
| Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 50k | N/A | 1949 |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1946 |
| Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | N/A | N/A | 1953 |
| Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1956 |
| Mr. T. J. Washburn Jr. | Principal Accounting Officer | N/A | N/A | 1981 |
| Dr. Clive Patience Ph.D. | Chief Technical Operations Officer | N/A | N/A | 1964 |
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Agios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 7; Compensation: 6.
